Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229–53. https://doi.org/10.1182/blood.2022015851.

Article  CAS  PubMed  Google Scholar 

Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo B, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours lymphoid neoplasms. Leukemia. 2022;36:1720–48. https://doi.org/10.1038/s41375-022-01620-2.

Article  PubMed  PubMed Central  Google Scholar 

Vose J, Armitage J, Weisenburger D. Project IT-CL. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30. https://doi.org/10.1200/JCO.2008.16.4558.

Article  PubMed  Google Scholar 

Bellei M, Foss FM, Shustov AR, Horwitz SM, Marcheselli L, Kim WS, et al. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective. Int T-Cell Project Haematol. 2018;103:1191–7. https://doi.org/10.3324/haematol.2017.186577.

Article  CAS  Google Scholar 

Yi JH, Kim JH, Baek KK, Lim T, Lee DJ, Ahn YC, et al. Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma. Ann Oncol. 2011;22:1636–43. https://doi.org/10.1093/annonc/mdq645.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Ellin F, Landström J, Jerkeman M, Relander T. Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study. Blood. 2015;126:36–41. https://doi.org/10.1182/blood-2014-12-616961. Largest published dataset on CNS relapse in PTCL with risk factor analysis.

Article  CAS  PubMed  Google Scholar 

Pro B, Perini G. Central nervous system prophylaxis in peripheral T-cell lymphoma. Blood. 2010;115:5427. https://doi.org/10.1182/blood-2010-02-266890.

Article  CAS  PubMed  Google Scholar 

Gurion R, Mehta N, Migliacci JC, Zelenetz A, Moskowitz A, Lunning M, et al. Central nervous system involvement in T-cell lymphoma: a single center experience. Acta Oncol. 2016;55:561–6. https://doi.org/10.3109/0284186X.2015.1118656.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, et al. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One. 2018;13:e0191461. https://doi.org/10.1371/journal.pone.0191461.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mocikova H, Pytlík R, Benesova K, Janikova A, Duras J, Sykorova A, et al. Peripheral T-cell lymphomas involving the central nervous system: a report from the Czech Lymphoma Study Group Registry. Front Oncol. 2022;12:874462. https://doi.org/10.3389/fonc.2022.874462.

Article  CAS  PubMed  PubMed Central  Google Scholar 

López-Guillermo A, Cid J, Salar A, López A, Montalbán C, Castrillo JM, et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L Classification. Ann Oncol. 1998;9:849–55. https://doi.org/10.1023/a:1008418727472.

Article  PubMed  Google Scholar 

Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31:1970–6. https://doi.org/10.1200/JCO.2012.44.7524.

Article  CAS  PubMed  Google Scholar 

Haioun C, Besson C, Lepage E, Thieblemont C, Simon D, Rose C, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin’s lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Ann Oncol. 2000;11:685–90. https://doi.org/10.1023/a:1008394827806.

Article  CAS  PubMed  Google Scholar 

Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102:4284–9. https://doi.org/10.1182/blood-2003-02-0542.

Article  CAS  PubMed  Google Scholar 

Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis ofnon-Hodgkin’s lymphoma: a risk model. Ann Oncol. 2002;13:1099–107. https://doi.org/10.1093/annonc/mdf175.

Article  CAS  PubMed  Google Scholar 

van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91:1178–84. https://doi.org/10.1182/blood.V91.4.1178.

Article  PubMed  Google Scholar 

Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma–a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Ann Oncol. 2007;18:149–57. https://doi.org/10.1093/annonc/mdl327.

Article  CAS  PubMed  Google Scholar 

Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin’s lymphoma: a 20-year follow-up analysis of SWOG 8516 – the Southwest Oncology Group. J Clin Oncol. 2009;27:114–9. https://doi.org/10.1200/JCO.2008.16.8021.

Article  PubMed  PubMed Central  Google Scholar 

Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, et al. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34:3150–6. https://doi.org/10.1200/JCO.2015.65.6520.

Article  CAS  PubMed  Google Scholar 

Bhansali RS, Ganesan N, Stuver RN, Horwitz SM, Wudhikarn K, Hwang SR, et al. A multi-institutional retrospective analysis of T-cell lymphomas with central nervous system relapse. Blood. 2021;138:1382–1382. https://doi.org/10.1182/blood-2021-148868.

Article  Google Scholar 

Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol. 2012;3:388. https://doi.org/10.3389/fmicb.2012.00388.

Article  PubMed  PubMed Central  Google Scholar 

Teshima T, Akashi K, Shibuya T, Taniguchi S, Okamura T, Harada M, et al. Central nervous system involvement in adult T-cell leukemia/lymphoma. Cancer. 1990;65:327–32. https://doi.org/10.1002/1097-0142(19900115)65:2%3c327::aid-cncr2820650224%3e3.0.co;2-w.

Article  CAS  PubMed  Google Scholar 

Patel R, Rahman S, Shah N, Thakkar A, et al. Predictors of central nervous system (CNS) involvement in North American adult T-cell leukemia lymphoma (ATLL) and their survival pattern. Blood. 2021;138:1400. https://doi.org/10.1182/blood-2021-151447.

Article  Google Scholar 

Kim SJ, Oh SY, Hong JY, Chang MH, Lee DH, Huh J, et al. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type? Ann Oncol. 2010;21:1058–63. https://doi.org/10.1093/annonc/mdp412.

Article  CAS  PubMed  Google Scholar 

•• Kim H, Jeong H, Yamaguchi M, Sohn I, Yoon SE, Byeon S, et al. Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. Blood. 2020;136:2548–56. https://doi.org/10.1182/blood.2020005026. A risk score developed for CNS relapse in patients with ENKTL that was validated in an external cohort.

Article  PubMed  Google Scholar 

•• Bhansali RS, Ellin F, Cao M, Relander T, Li W, Long Q, et al. CNS relapse in T-cell lymphoma index: a risk score to predict central nervous system relapse in patients with T-cell lymphomas. Blood. 2022;140:1481–4. https://doi.org/10.1182/blood-2022-160090. Preliminary data presented at the American Society of Hematology meeting for a new risk score to predict CNS relapse in patients with PTCL.

Article  Google Scholar 

• Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022;139:413–23. https://doi.org/10.1182/blood.2021012888. Large retrospective study demonstrating no benefit to CNS prophylaxis for high-risk B-cell NHL.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, et al. T-cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:285–308. https://doi.org/10.6004/jnccn.2022.0015.

Article  CAS  PubMed  Google Scholar 

• Cook LB, Fuji S, Hermine O, Bazarbachi A, Ramos JC, Ratner L, et al. Revised adult T-cell leukemia-lymphoma international consensus meeting report. J Clin Oncol. 2019;37:677–87. https://doi.org/10.1200/JCO.18.00501. Updated recommendations for diagnosis and treatment of ATLL, along with discussion about CNS screening and prophylactic therapy.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsukasaki K, Tobinai K, Shimoyama M, Kozuru M, Uike N, Yamada Y, et al. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol. 2003;77:164–70. https://doi.org/10.1007/BF02983215.

Article  CAS  PubMed  Google Scholar 

Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113:375–82. https://doi.org/10.1046/j.1365-2141.2001.02737.x.

Article  CAS  PubMed  Google Scholar 

Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25:5458–64. https://doi.org/10.1200/JCO.2007.11.9958